Summary & Overview
HCPCS J8655: Netupitant 300 mg and Palonosetron 0.5 mg, Oral
HCPCS Level II code J8655 denotes netupitant 300 mg combined with palonosetron 0.5 mg in an oral formulation, a guideline-aligned therapy for preventing chemotherapy-induced nausea and vomiting (CINV). This code captures the administration of a fixed-dose oral antiemetic regimen commonly used in oncology supportive care nationally. Its correct use affects medication coverage, billing for oncology practices, and patient access to guideline-directed prophylaxis.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, payer coverage considerations, and areas where benchmarks or policy updates typically influence billing for oral oncologic supportive medications. The publication outlines common billing themes such as site-of-service implications, coding accuracy, and interactions with pharmacy dispensing channels. It also summarizes what to expect in payer policies and where documentation and administration patterns commonly drive claim outcomes.
The report is intended to inform revenue cycle and clinical teams, pharmacy directors, and policy analysts about the coding purpose, typical use cases, and the landscape of payer engagement for this oral antiemetic product.
Billing Code Overview
HCPCS Level II code J8655 represents netupitant 300 mg and palonosetron 0.5 mg, oral. This combination oral antiemetic is used for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is administered as an oral medication.
-
Service Type: Oral antiemetic medication
-
Typical Site of Service: Outpatient clinics, oncology infusion centers, and retail or specialty pharmacies for oral administration prior to or alongside chemotherapy regimens.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient scheduled to receive highly emetogenic chemotherapy (for example, cisplatin-based or anthracycline/cyclophosphamide regimens) who requires oral antiemetic prophylaxis. The medication J8655 (netupitant 300 mg and palonosetron 0.5 mg, oral) is administered prior to chemotherapy on the day of infusion as part of an antiemetic regimen to prevent acute and delayed chemotherapy-induced nausea and vomiting. Clinical workflow: patient check-in and verification of chemotherapy order; nurse or pharmacist verifies indication and dose, documents allergies and prior antiemetic response; medication is dispensed by the outpatient pharmacy or oncology infusion center; the oral tablet is given or observed taken by nursing 60 minutes before chemotherapy per institutional protocol; nursing documents administration time, lot number, and any immediate adverse effects in the medical record; antiemetic efficacy and delayed symptoms are assessed during follow-up visits or by telephone within 48–72 hours after chemotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Professional component | Use when billing for the professional component of a service distinct from facility supplies related to medication administration when applicable. |